Richard Laing

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi Ten recommendations to improve use of medicines in developing countries
    R Laing
    Boston University School of Public Health, 715 Albany Street, Boston, MA 02118, USA
    Health Policy Plan 16:13-20. 2001
  2. ncbi 25 years of the WHO essential medicines lists: progress and challenges
    Richard Laing
    Boston University School of Public Health, Boston, MA 02118, USA
    Lancet 361:1723-9. 2003
  3. ncbi Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs
    R O Laing
    Department of International Health, Boston University School of Public Health, Massachusetts 02118, USA
    Int J Tuberc Lung Dis 4:S194-207. 2000
  4. ncbi The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries
    Shanti Mendis
    Department of Chronic Diseases and Health Promotion, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 85:279-88. 2007
  5. ncbi Prices & availability of common medicines at six sites in India using a standard methodology
    Anita Kotwani
    Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, India
    Indian J Med Res 125:645-54. 2007

Collaborators

  • Nathan Ford
  • Andy Gray
  • Brenda Waning
  • Shanti Mendis
  • Margaret Ewen
  • Anita Kotwani
  • G L Singhal
  • P K Lakshmi
  • Santanu Tripathi
  • Shobha Iyer
  • Alexandra Cameron
  • Dalia Dey
  • Keiko Fukino
  • Vijay Thawani
  • Oussama Khatib
  • Archana Patel
  • Jerzy Leowski
  • Anthonio Filipe
  • Kannamma Raman

Detail Information

Publications5

  1. ncbi Ten recommendations to improve use of medicines in developing countries
    R Laing
    Boston University School of Public Health, 715 Albany Street, Boston, MA 02118, USA
    Health Policy Plan 16:13-20. 2001
    ..Sufficient evidence is now available to persuade policy-makers that it is possible to promote rational drug use. If such effective strategies are followed, the quality of health care can be improved and drug expenditures reduced...
  2. ncbi 25 years of the WHO essential medicines lists: progress and challenges
    Richard Laing
    Boston University School of Public Health, Boston, MA 02118, USA
    Lancet 361:1723-9. 2003
    ..This approach has required an engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and research and development to ensure availability of new essential medicines...
  3. ncbi Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs
    R O Laing
    Department of International Health, Boston University School of Public Health, Massachusetts 02118, USA
    Int J Tuberc Lung Dis 4:S194-207. 2000
    ....
  4. ncbi The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries
    Shanti Mendis
    Department of Chronic Diseases and Health Promotion, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 85:279-88. 2007
    ..To assess the availability and affordability of medicines used to treat cardiovascular disease, diabetes, chronic respiratory disease and glaucoma and to provide palliative cancer care in six low- and middle-income countries...
  5. ncbi Prices & availability of common medicines at six sites in India using a standard methodology
    Anita Kotwani
    Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, India
    Indian J Med Res 125:645-54. 2007
    ..Data on prices and availability of common medicines in public and private sector in different States of India are scarce. Hence, surveys were undertaken in different States of India to evaluate these metrics...